跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT07544160
NCT07544160尚未招募1 期

A Single-arm, Open-label Phase I Clinical Study to Evaluate ICG318 CAR-T in Adults With Refractory Inflammatory Bowel Disease

iCell Gene Therapeutics1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2026年4月7日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施

试验速览

阶段
1 期
状态
尚未招募
发起方
入组人数
18
试验地点
1
主要终点
Number of Adverse Events (AEs) after ICG318 CAR-T infusion.
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This is a Phase I, IIa, Single-Arm, interventional, open label, treatment study to evaluate the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with relapsed and/or refractory inflammatory bowel disease.

详细描述

Inflammatory bowel disease (IBD) is a chronic, immune-mediated disease of the gastrointestinal (GI) tract. IBD may result in GI lesions as well as extraintestinal manifestations affecting the joints, skin, eyes, and biliary system. IBD is driven by humoral immune cells including B cells, plasma cells and long-lived plasma cells.

ICG318 CAR-T, the investigational agent in this clinical trial, is an armored, compound chimeric antigen receptor (cCAR) composed of two independently functioning CARs that target the CD19 surface antigen and the BCMA surface antigen on B cells and plasma/long-lived plasma cells, respectively.

This study is being conducted to evaluate the safety and efficacy of ICG318 CAR-T in patients with refractory IBD. A single dose of ICG318 CAR-T will be evaluated after cyclophosphamide and fludarabine lymphodepletion.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Sequential
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •All subjects or legal guardians must sign an ethics committee-approved informed consent form in writing prior to initiation of any screening procedures.
  • •Male or female subject over 18 years old and under 70 years old at the time of evaluation; Weight ≥ 40 kg.
  • •Diagnosed with inflammatory bowel disease assessed by the investigator and the disease course has been ≥ 3 months before signing informed consent (clinical manifestations, endoscopy and histopathological reports consistent with the diagnosis of inflammatory bowel disease are required).
  • •The subject has documented inadequate response, loss of response, or intolerance to at least one advanced therapy for IBD.
  • •Patients with IBD during the screening period need to meet the requirements of moderate to severe IBD; UC: active ulcerative colitis, defined as per the adapted Mayo score criteria. CD: CD subjects with moderate to severe active CD, defined as interpreted by SES-CD.
  • •Life expectancy greater than 6 months;
  • •Female individuals with fertility (defined as all females who are physiologically capable of becoming pregnant) must provide informed consent, have a negative blood pregnancy test result, and agree to use highly effective contraception from the time of informed consent until 1 year after CAR-T cell infusion. Male individuals with fertility must agree to use effective barrier contraception from the time of informed consent until 1 year after CAR-T cell infusion, and should not donate semen or sperm during the entire study period.
  • •Indeterminate colitis is permitted.

排除标准

  • •Subjects who have previously received any BCMA and/or CD19 targeted cell therapy products or CAR-T therapy for any target before signing the informed consent form.
  • •Undiagnosed type colitis, fulminant colitis, Hirschsprung-associated enterocolitis (HAEC), microscopic colitis, ischemic colitis, radiation colitis, colitis-related diverticular disease, or other colitis or enteritis type that may confound the evaluation of efficacy.
  • •Subjects with malignant tumors or dysplasia on endoscopy.
  • •Subjects with severely impaired vital organ function.
  • •Impaired bone marrow function.
  • •Active hepatitis B, HCV positive, HIV antibody positive, Treponema pallidum antibody positive, Active tuberculosis.
  • •Presence of any IBD related complications determined by the investigator to interfere with the study of ICG318 CAR-T in refractory IBD.
  • •History of bleeding within 30 days determined by the investigator to exclude the patient.
  • •Infectious diseases: subjects with acute, life-threatening bacterial, viral or fungal infections that have not been controlled.
  • •Hospitalization for IBD-related complications within 30 days prior to screening.
  • •11） Clinically significant central nervous system disease determined by the investigator to impair the subjects ability to participate safely in this trial.
  • •12） Subjects with prior or concurrent malignancies. Exceptions may be determined at the discretion of the investigator.
  • •13） Vaccination within 30 days before screening and vaccination within 3 months after planned cell ICG318 CAR-T infusion.
  • •14） Subjects who are receiving or have received another investigational drug or drugs without adequate washout time as determined by the principal investigator.
  • •15） Those who are judged by the investigator to be unfit for leukapheresis, or whose IBD disease severity and trajectory are not compatible with infusion with ICG318 CAR-T cells, or any critical steps of the trial evaluation such as but not limited to contraindications to colonoscopy.
  • •16） Female subjects who are pregnant or lactating. 17） Autoimmune diseases judged by the investigator to require systemic treatment and affect the evaluation of efficacy.
  • •18） Suicidal tendencies, tobacco use, substance use, or alcohol abuse as determined by the investigator.
  • •19） Those who have a history of a severe drug allergy, or are allergic to the test drug ingredients, excipients or combined therapeutic drugs.
  • •20） Other conditions that the investigator believes should not participate in this clinical trial.

研究组 & 干预措施

Single Arm Biologic Infusion

Experimental

干预措施: ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T (Biological)

结局指标

主要结局

Number of Adverse Events (AEs) after ICG318 CAR-T infusion.

时间窗: Starting day 0 and up to 2 years after ICG318 CAR-T infusion.

Number of participants with AEs, Serious Adverse Events (SAEs), Treatment Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESI), and Dose Limiting Toxicities (DLTs).

次要结局

  • Determine the recommended phase 2 dose (RP2D) regimen.(Starting day 0 and assessed 2 years after ICG318 CAR-T infusion.)
  • The proportion of subjects who achieved drug-free remission.(At 6 months, 12 months, 24 months after ICG318 CAR-T infusion.)
  • Fecal calprotectin levels.(28 days, 2 months, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months after ICG318 CAR-T infusion.)
  • Cmax(Assessed as per schedule of events up to 2 years after ICG318 CAR-T infusion.)
  • Tmax(Assessed as per schedule of events up to 2 years after ICG318 CAR-T infusion.)
  • T1/2(Assessed as per schedule of events up to 2 years after ICG318 CAR-T infusion.)
  • AUC(Assessed as per schedule of events up to 2 years after ICG318 CAR-T infusion.)
  • Rate of B cell elimination and naïve B-Cell recovery(Assessed as per schedule of events up to 2 years after ICG318 CAR-T infusion.)
  • Recovery of immunoglobulins(Assessed as per schedule of events up to 2 years after ICG318 CAR-T infusion.)
  • The proportion of subjects who achieved clinical remission from Crohn's Disease (CD)(3 months, 6 months, 12 months, 18 months, 24 months after ICG318 CAR-T infusion.)
  • The proportion of subjects who achieved clinical response from CD(3 months, 6 months, 12 months, 18 months, 24 months after ICG318 CAR-T infusion.)
  • The proportion of subjects who achieved endoscopic remission from CD(12 months, 24 months after ICG318 CAR-T.)
  • The proportion of subjects who achieved endoscopic response from CD(12 months, 24 months after ICG318 CAR-T.)
  • Histological Remission from CD(12 months, 24 months after ICG318 CAR-T.)
  • The proportion of subjects who achieved clinical remission from Ulcerative Colitis (UC)(3 months, 6 months, 12 months, 18 months, 24 months after ICG318 CAR-T infusion.)
  • The proportion of subjects who achieved clinical response from UC(3 months, 6 months, 12 months, 18 months, 24 months after ICG318 CAR-T infusion.)
  • The proportion of subjects who achieved endoscopic remission from UC(12 months, 24 months after ICG318 CAR-T infusion.)
  • The proportion of subjects who achieved endoscopic response from UC(12 months, 24 months after ICG318 CAR-T infusion.)
  • Histological remission from UC(12 months, 24 months after ICG318 CAR-T infusion.)

研究者

发起方
iCell Gene Therapeutics
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

尚未招募
1 期
A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
NCT07333573Shanghai Zhongshan Hospital42
招募中
2 期
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
NCT07286292Institut de Recherches Internationales Servier (I.R.I.S.)10
尚未招募
2 期
A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Majorβ-thalassemia Major
NCT07489196CorrectSequence Therapeutics Co., Ltd20
尚未招募
1 期
An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined With NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS).Multiple Sclerosis
NCT07546110The Affiliated Hospital of Xuzhou Medical University20
招募中
1 期
U69-CART-Cells For R/R T-ALL
NCT07350863The First Affiliated Hospital of Soochow University12